The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | MAVORIC: mogamulizumab improves PFS for CTCL
Julia Jane Scarisbrick, MBChB, FRCP, MD, University Hospital Birmingham, Birmingham, UK, discusses the findings of the Phase III randomized MAVORIC trial (NCT01728805) comparing the outcomes of patients with relapsed or refractory (R/R) cutaneous T-cell lymphoma (CTCL) who receive mogamulizumab versus vorinostat. Prof. Scarisbrick reports that the trial, which enrolled over 350 patients, demonstrated a significant progression-free survival (PFS) benefit amongst patients receiving mogamulizumab. Prof. Scarisbrick also highlights that there was an improvement in quality of life amongst patients receiving mogamulizumab. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
